Disclosures

• None –
• No financial conflict of interest.
• No unapproved drugs or devices will be discussed.
Objectives

• Discuss the successes in Nuclear Medicine achieved by SNMMI and SNMMI-TS
• Discuss the Value Initiative of SNMMI, and how it will bring value to Nuclear Medicine practice and the field of Nuclear Medicine
• Discuss the continuing challenges encountered by Nuclear Medicine physicians and technologists
SNMMI’s HISTORY

- Founded in 1954
- The largest international scientific organization dedicated to nuclear medicine and radionuclide therapy
- A multidisciplinary organization
  - 15,000 physicians, scientists, pharmacists and technologists
  - Industry partners interested in the diagnostic, therapeutic and investigational uses of molecular imaging and therapy agents, instrumentation and techniques
Bennett S. Greenspan, MD, FACNM, FACR  
President

Satoshi Minoshima, MD, PhD  
President-Elect

Kathleen M. Krisak, BS,CNMT, FSNMMI-TS  
President, TS

Vasken Dilsizian, MD  
Vice President-Elect

Norman E. Bolus, MSPH,CNMT,FSNMMI-TS  
President-Elect, TS
## Membership Summary - 2017

<table>
<thead>
<tr>
<th>Category</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full</td>
<td>3,639</td>
</tr>
<tr>
<td>Associate</td>
<td>281</td>
</tr>
<tr>
<td>Affiliate</td>
<td>268</td>
</tr>
<tr>
<td>Lab Professionals</td>
<td>58</td>
</tr>
<tr>
<td>Technologists</td>
<td>7,914</td>
</tr>
<tr>
<td>Emeritus/Honorary</td>
<td>1,148</td>
</tr>
<tr>
<td>Residents</td>
<td>585</td>
</tr>
<tr>
<td>Scientist Students</td>
<td>198</td>
</tr>
<tr>
<td>Tech Students</td>
<td>901</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>14,992</strong></td>
</tr>
</tbody>
</table>
## Members by Area of Practice

<table>
<thead>
<tr>
<th>Area of Practice</th>
<th>Members</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiology</td>
<td>1,204</td>
</tr>
<tr>
<td>Medical Physics</td>
<td>343</td>
</tr>
<tr>
<td>Molecular Imaging</td>
<td>850</td>
</tr>
<tr>
<td>Molecular Probe &amp; Contrast Agent Development</td>
<td>54</td>
</tr>
<tr>
<td>Nanomedicine</td>
<td>10</td>
</tr>
<tr>
<td>Nuclear Medicine</td>
<td>4,972</td>
</tr>
<tr>
<td>Nuclear Medicine Technology</td>
<td>1,808</td>
</tr>
<tr>
<td>Optical Imaging</td>
<td>10</td>
</tr>
<tr>
<td>Radiology</td>
<td>1,339</td>
</tr>
<tr>
<td>Radiopharmaceutical Chemistry</td>
<td>282</td>
</tr>
<tr>
<td>Radiopharmacy</td>
<td>134</td>
</tr>
<tr>
<td>Other</td>
<td>353</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>11,359</strong></td>
</tr>
</tbody>
</table>
### Membership Summary - 2017

<table>
<thead>
<tr>
<th>Member by Place of Work</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Academic Institution</td>
<td>2,611</td>
</tr>
<tr>
<td>Academic Research Center</td>
<td>71</td>
</tr>
<tr>
<td>Departmental Library</td>
<td>5</td>
</tr>
<tr>
<td>Free Standing Imaging Facility</td>
<td>1,252</td>
</tr>
<tr>
<td>Government Laboratory</td>
<td>107</td>
</tr>
<tr>
<td>Industry</td>
<td>673</td>
</tr>
<tr>
<td>Institutional Library</td>
<td>4</td>
</tr>
<tr>
<td>Medical Center</td>
<td>1,161</td>
</tr>
<tr>
<td>Military Clinic/Hospital</td>
<td>428</td>
</tr>
<tr>
<td>Mobile Unit</td>
<td>230</td>
</tr>
<tr>
<td>Molecular Imaging Laboratory</td>
<td>76</td>
</tr>
<tr>
<td>Non-University Affiliated Hospital</td>
<td>3,236</td>
</tr>
<tr>
<td>University Affiliated Medical Center</td>
<td>559</td>
</tr>
<tr>
<td>Other</td>
<td>405</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>10,818</td>
</tr>
</tbody>
</table>

![Pie chart showing distribution of members by place of work](chart.png)
These are exciting times for Nuclear Medicine and Molecular Imaging!

New therapies, devices and drugs are making nuclear medicine an essential tool in oncology, neurosciences, cardiology and other clinical applications.

We face challenges that we can overcome by working together to elevate the value of imaging practices and bring the highest-quality care and value to patients.

This is a time to collaborate with our colleagues in the field, and our industry partners to demonstrate our capacity to provide tailored, precise, valuable, diagnostic and therapeutic care to patients.
A Vision for the Future

At SNMMI, we have a new vision for leadership in our field:

The Value Initiative

The Value Initiative is the Society’s strategy and roadmap for working with industry and other partners to demonstrate the crucial role of NM/MI to the medical community, regulators, patients, and to the public.

We believe that by working together we can bring greater value to the fields of imaging and medicine, advancing scientific discovery and further improving patient outcomes.
The Value Initiative forms the basis of SNMMI’s new strategic plan, and focuses on six key domains:

1. Quality of Practice
2. Research and Discovery
3. Workforce Pipeline and Life-Long Education
4. Advocacy
5. Outreach
6. Organizational Strength and Stability

Work in these domains adds a new layer of value to the Society’s existing work, with the goal of bringing that value to patients, the medical field, and society at large.
Primary Focus of the Value Initiative Domains

- **Quality of Practice** is about raising the standard of diagnostic and therapeutic practices in our field.

- **Research and Discovery** is about research, development and the marketing of related drugs and devices essential to the vitality and growth of the specialty.

- Attracting and educating new talent is at the heart of **Workforce Pipeline and Life-Long Learning**.

- **Advocacy** centers around promoting awareness among policymakers about our field, particularly on the issue of reimbursement services.

- **Outreach** is focused on communicating the value of the specialty to patients, providers, academia and industry.

- **Organizational Strength and Stability** ensures long term leadership by the Society for the field.
Mission: To improve human health by advancing nuclear medicine, molecular imaging, and radionuclide therapy.

Vision: SNMMI will be the leader in unifying, advancing, and optimizing nuclear medicine, molecular imaging and radionuclide therapy.

Core Values:
- Excellence in Patient Care
- Integrity (includes honesty and ethics)
- Respect for all People and Ideas
- Life Long Learning
- Fostering Inquiry and Reflection
- Visionary Leadership
- Excellence, Professionalism and Collaboration

Primary Themes:
- Advocacy
- Research & Discovery
- Outreach
- Quality of Practice
- Workforce Pipeline & Life-Long Learning
- Org. Strength & Stability

Promoting Value
- Research
- Advocacy
- Outreach

Quality Practice and Life-Long Learning
- Ensuring Workforce pipeline
- Develop Quality Measures
- Guidance documents
- Creating education plan

Member Enhancement & Org. Stability
- Membership Engagement
- Volunteer Enhancement
- Financial stability
• **Quality of Practice** – Gary Dillehay, MD, FACNM, FCR

• **Research and Discovery** – Richard Wahl, MD

• **Workforce Pipeline and Life-Long Learning** – Frederick Grant, MD

• **Advocacy** – Munir Ghesani, MD

• **Outreach** – Vasken Dilsizian, MD

• **Organizational Strength and Stability** – SNMMI BoD
• The Value Initiative is led by a **Value Initiative Board**, chaired by Satoshi Minoshima, MD, PhD - SNMMI President-Elect

• The Value Initiative Board is composed of the chairs for each of the six domains and the SNMMI Leadership.

• SNMMI’s governance committees are organized under each of the domains.

• Industry will have input to the Value Initiative Board through the **Value Initiative Industry Alliance**.
Domain: Quality of Practice

Goal A: SNMMI members are known for high-quality, value-driven performance and delivery of patient-centered nuclear medicine practice

Objectives:
- Increase the development and dissemination of clinical guidance documents, including appropriate use criteria
- Ensure the development of value/quality metrics for nuclear medicine
- Standardize best practices to enhance operational efficiency
- Expand continuing education options for practitioners
- Facilitate new service lines in nuclear medicine clinical settings
- Improve recognition of the value of nuclear medicine with radiology practice
On March 31, 2014, Congress passed the “Protecting Access to Medicare Act of 2014” (PAMA) that tied physician reimbursement to the use of Appropriate Use Criteria (AUC).

Section 218(b) of PAMA established a new program under the statute for fee-for-service Medicare to promote the use of AUC for Advanced Diagnostic Imaging Services (ADIS), including CT, MRI as well as all nuclear medicine procedures, including PET.

Under this program, AUC may be developed only by organizations that are deemed as ‘qualified provider-led entities (qPLEs) by CMS.

The society was approved as a qualified PLE in June 2016.

PAMA requires referring physicians to consult AUC developed by a PLE to ensure cost-effective and appropriate utilization of ADIS.

Proposed implementation date for this program is now January 1, 2020.
SNMMI AUC Development Project

- SNMMI modeled its AUC development process after the RAND/UCLA criteria and includes a systematic review of evidence followed by development of AUC for various common clinical scenarios using a modified Delphi approach.

- This process is also consistent with the Institute of Medicine’s standards for developing trustworthy clinical guidance documents.

- The process included identification of relevant clinical scenarios, a systematic synthesis of available evidence, individual and group ratings of the scenarios using a formal consensus process, and drafting the final AUC document based on the group ratings and discussions.

- To conduct independent and objective systematic review of the evidence, SNMMI has an ongoing contract with the Oregon Health and Science University’s Evidence-based Practice center.

- The primary purpose of these systematic reviews is to assess the diagnostic accuracy and comparative effectiveness of selected nuclear medicine procedures in clinical decision making and patient outcomes.
SNMMI AUC Development Project

• To provide a comprehensive library of AUC for the high value-high volume nuclear medicine procedures, the SNMMI Guidance Oversight Committee (GOC) has set a goal of developing 4-5 AUC each year for the next several years

• AUC under development for 2016-2017 – Status

❖ Bone scintigraphy in breast and prostate cancer – Approved by SNMMI Board, excerpts and summary published in JNM, posted on SNMMI website.

❖ Ventilation perfusion imaging in pulmonary embolism – Approved by SNMMI Board, excerpts and summary published in JNM, posted on SNMMI website.

❖ Hepatobiliary scintigraphy in abdominal pain – Approved by SNMMI Board. Excerpts and summary published in JNM, posted on SNMMI website.

❖ FDG PET/CT restaging and response assessment of malignant disease – Approved by SNMMI Board, AUC document published in JNM in 2017

• SNMMI AUC documents can be accessed at http://www.snmmi.org/auc
SNMMI AUC Development Project

• AUC under development for 2017-2018 – Status


❖ **Infection imaging** – Expert workgroup currently in the process of finalizing clinical indications. Anticipated completion by 1st quarter of 2018.


❖ **Prostate cancer imaging** – Collaborating with ASCO to develop guideline using the same evidence base as ASCO’s clinical practice guideline for Prostate Cancer Imaging. Anticipated completion by 2nd quarter of 2018.

❖ **Nuclear medicine procedures for diagnosis and therapy in thyroid cancer** – The workgroup is evaluating clinical indications. Anticipated completion by 2nd quarter of 2018.
• Per PAMA legislation, prior to ordering any Advanced Diagnostic Imaging Services (ADIS), the referring physicians must consult AUC via an approved Clinical Decision Support Mechanism (CDSM)

• While developing a comprehensive library of AUC for high volume, high value nuclear medicine procedures, the society has also been working with many of the leading vendors to explore collaboration for the dissemination of these AUC via CDSMs

• SNMMI has signed contracts with the following two qualified CDSM vendors:
  
   National Decision Support Company – the provider of ACR Select/Care Select
  
   Stanson Health
Multi-Lateral Consensus Conference

- January 12-14, 2018, in Martinique
- SNMMI, European Association of Nuclear Medicine (EANM), the American Thyroid Association (ATA) and the European Thyroid Association (ETA)
- Meeting Focus:
  - How to expand dialogue between the societies (dialogue about education, research, appropriate use, white papers, guidelines, etc.)
  - Indications and administration for I-131 adjuvant therapy (risk stratification included here)
  - Optimal prescribed activity of I-131 for adjuvant therapy
  - Definitions of iodine-refractory disease – 1. therapy is necessary, 2. Radioactive iodine is deemed the most appropriate therapy, 3. goals of I-131 therapy are not achieved.
Domain: Research and Discovery

Goal B: SNMMI has **advanced the development and approval** of nuclear medicine and molecular imaging technologies

Objectives:
- Encourage and promote research in the field
- Increase the number of initiatives targeting the discovery and validation of diagnostic radiopharmaceuticals, radiotherapeutics and instrumentation
- Improve the quality of nuclear medicine studies and literature
- Increase funding for research awards
- Enhance research on how nuclear medicine data can be implemented clinically in conjunction with informatics, etc
The Scanner Validation Program was established to provide relevant and meaningful assurances to trial sponsors that PET/CT scanners in their trials will perform quantitatively and qualitatively above predetermined standards.

Building on the success and data of the scanner validation program, CTN is developing a phantom program to meet the new Joint Commission requirements.

The Joint Commission project directly addresses:

- Quality of Practice Domain
  - Goal 2: Ensure the development of value/quality metrics for nuclear medicine.
  - Goal 3: Standardize the best practices for enhance operational efficiency.
  - Goal 5: Facilitate new service lines in NM clinical settings.
- Outreach Domain
  - Goal 5: Increase outreach to hospital administrators.
- Organizational Strength and Stability Domain
  - Goal 1: Strengthen membership numbers.
  - Goal 2: Ensure financial stability.

CTN oncology chest phantom has validated over 300 scanners worldwide.
Approval of New Agents

- Axumin™
  - Blue Earth Diagnostic’s [F-18]Fluciclovine – Axumin™ was approved on May 27, 2016 for PET imaging of in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.

- NETSPOT™
  - AAA’s [Ga-68]DOTATATE – NETSPOT™ was approved on June 1, 2016 for PET detection of neuroendocrine tumors in adult and pediatric patients.

- Currently working on [Ga-68] PSMA for primary and biochemical recurrent prostate cancer and a regulatory solution for F-DOPA
CTN has developed reader training programs to help physicians learn how to acquire and interpret Axumin™, NETSPOT™, 68Ga-DOTATOC scans. All three training courses are available through the NMCTG website for free.

- **Axumin™**: Over 440 completed training
- **NETSPOT™**: Over 350 completed training
CTN Education Program

CTN has developed a wide array of imaging research-specific courses and webinars including:

- An annual webinar series on hot topics
- A comprehensive course curriculum
- New this year: A technologist-focused series of webinars on normal and diseased anatomy, taught by physicians, including
  - Head and Neck
  - Brain
  - Male and Female pelvis
  - Abdominal
Education Program and Training for New Agents

- Both education curriculum and training initiatives associated with new agents directly address:
  - **Quality of Practice Domain**
    - Goal 3: Standardize best practices to enhance operational efficiency.
    - Goal 4: Expand continuing education options for practitioners.
    - Goal 5: Facilitate new service lines in nuclear medicine clinical settings
  - **Workforce Pipeline and Life-Long Learning Domain**
    - Goal 3: Increase recognition of SNMMI as the professional home of all nuclear medicine professionals.
  - **Organizational Strength and Stability Domain**
    - Goal 1: Strengthen membership numbers.
• NCI and SNMMI previously held two workshops on TRT, in 2013 and 2014.

• NCI and SNMMI are holding a Round Table Discussion on Targeted Radiotherapy: From Research to Clinical Practice on September 12, 2017

• Meeting Focus: How to advance Targeted Radiotherapy (TRT) research from basic physics, chemistry and radiobiology to translational and clinical trials with the ultimate goal of increasing the incorporation of TRT into clinical practice.
Lu-177 dotatate FDA-approved – Jan. 26, 2018

- Lutetium-177 dotatate (Lutathera) has recently been approved by the FDA for treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS).
AACR-SNMMI Joint Conference

- **State-of-the-Art Molecular Imaging in Cancer Biology and Therapy**
  - February 14 - 17, 2018
  - Hard Rock Hotel
  - San Diego, California, USA
  - Abstract submission deadline: Friday, October 31
  - Advance registration deadline: Friday, December 19
Small Business Advocacy Alliance (SBAA)

- The SNMMI Small Business Advisory Alliance (SBAA) provides a forum for start-ups, venture firms and other small businesses to collaborate with SNMMI in developing services and networking opportunities that help businesses address growth challenges and achieve greater success.

- CTN is currently working with multiple small companies assisting with new drug development, trial design and implementation.

- SBAA initiative *directly addresses*:
  - Research and Discovery Domain
    - Goal 1: Encourage and promote research in the field.
  - Quality of Practice Domain
    - Goal 5: Facilitate new service lines in nuclear medicine clinical settings
  - Outreach Domain
    - Increase SNMMI’s outreach efforts and resources within the imaging community.
The Journal of Nuclear Medicine

- Comprehensive body of nuclear medicine articles spanning the entire field—from basic science through clinical research
- Since 1960, an essential force within SNMMI and the field of nuclear medicine
- Influence steadily increasing

![Graphs showing Total Cites and Immediacy index from 2007 to 2016]
• Goals of new editor: Johannes Czernin, MD
  − Report and promote scientific discoveries, their translation, and their implementation
  − Invite and encourage fierce discussion
  − Serve as a megaphone for basic and translatable as well as clinical research discoveries that
    ▪ are conceived with a purpose
    ▪ have potential to improve outcome of our patients

• Results to date:
  − In Jan-July 2017, usage increased 16% over the previous year

• Theranostics supplement: September 2017
**Domain:** Workforce Pipeline and Life-Long Learning

**Goal C:** There is an appropriate number of qualified professionals working in the field of nuclear medicine

Objectives:
- Increase the supply of physicians qualified to practice nuclear medicine
- Increase the supply of qualified nuclear medicine scientists
- Increase recognition of SNMMI as the professional home of all nuclear medicine professionals
- Increase awareness of nuclear medicine and molecular imaging as an appealing and rewarding field for students interested in STEM careers (all professions – medicine, technologists, scientists)
- Increase recognition of nuclear medicine technologists as the technologist experts in performing nuclear medicine imaging and therapy
PET/MR Credentialing Statement

- American College of Radiology / SNMMI joint effort

- Published April 2015 – ACR/SNMMI Approve Joint Credentialing Statement for PET/MR: Brain

- Published May 2017 - ACR/SNMMI Approve Joint Credentialing Statement for PET/MR: Body

- Next Focus – Cardiology – Due out Spring 2018
Collaboration with ISMRM

- International Society for Magnetic Resonance in Medicine (ISMRM) collaboration.
- October 26-29, 2017 / The Blackstone (Chicago, IL)
- Early Registration Open (through September 28, 2017)

Focus of Workshop:
- technical aspects of positron emission tomography (PET) Magnetic Resonance Imaging (MRI)
- clinical utility of PET/MRI.
- Sessions on technical developments such as novel MR attenuation correction techniques and approaches to motion correction.
• Next Academy – 2018 in Orlando, FL
  – Applications Status – CLOSED!
  – Selections will be made in October and candidates will be notified.

• Eligibility
  – Must be a current resident, fellow, or in-training scientist;  OR
  – Must be within the first 7 years after residency or training completion, post-doctoral training or nuclear pharmacy training AND
  – Must be a member of the SNMMI for at least the past year (2016-2017)
Professional Development: Henkin and Slosky Fellowships

- **Henkin Fellowship** – Ashley Mishoe, UCSF and Daniel Yokell, MGH
  2017 Robert E. Henkin Government Relations Fellows
  - Program designed for young professionals
  - Week in DC learning the federal legislative and regulatory processes
  - Advocated on Capitol Hill and met with FDA, CMS, NIH, NRC, DOE/NNSA, OSTP White House officials plus ASNC and ASCO

- **Slosky Fellowship** – David Douglas, Stanford – 2017 Ursula Mary Kocemba-Slosky, PhD, Professional Relations Fellowship recipient
  - Program designed for young professionals to learn about intersociety relations
  - Week in DC learning how SNMMI interacts with medical societies and other professional organizations
  - Met with ACR, ASNC, ACC, CORAR, MITA, AdvaMed, etc.
  - Advocated on Capitol Hill and met with DOE
SEPTEMBER – Women in Medicine Month

• Celebrate Women in Medicine Month

• Join SNMMI throughout September as we celebrate Women in Medicine Month and Women in Nuclear Medicine.

• We thank them for their tireless efforts to support the advancement of women in medicine and nuclear medicine!

• snmni.org/WIMmonth
Women in Nuclear Medicine (WINM)

- WINM Event Held every Annual Meeting.
- WINM e-newsletter was distributed bi-annually.
- Virtual Book Clubs on a Quarterly Basis (Free)
International Collaboration

Nuclear Medicine Global Initiative

To encourage global collaboration in education; to harmonize procedure guidelines and other policies or to improve quality and safety.

- Organizations involved:
  - Nuclear medicine societies – China, Japan, Korea, India, Australia/New Zealand, Canada, South Africa
  - Multinational organizations – EANM, IAEA, WFNMB, ALASBINM, AOFNMB


- 2nd Project – *Availability of Radiopharmaceuticals* – aims to establish the availability, use, access issues and impediments to the use of diagnostic and therapeutic radiopharmaceuticals globally.
International Participation in SNMMI

The 2017 Annual Meeting
- A total of 5,030 attendees representing 56 countries.
- 28% of the attendees were from outside the U.S.
- 2,211 scientific abstracts were submitted

The Journal of Nuclear Medicine
- >1,150 submissions a year, 73% of which are international
Value Initiative Domain: Advocacy

Domain: Advocacy

Goal D: Policymakers understand the contribution of the nuclear medicine and molecular imaging field to improving patient outcomes

Objectives:

- Seek improvements in the integrity of the isotope supply chain and components
- Improve understanding among those developing new radiotracers and radiotherapeutics of what type of evidence is needed by the FDA to approve these items as “safe and effective” and by CMS to determine that they are “reasonable and necessary”
- Ensure adequate and appropriate reimbursement for nuclear medicine and molecular imaging procedures
- Enhance state-level advocacy
- Address U.S. pharmacopeia compounding issues
- Increase visibility with Federal legislators (i.e., sponsor an event, education programs, and/or an awards ceremony to raise awareness and recognize the work of those supporting pro-NM/MI legislation)
Seek Improvements in Isotope Supply

- Increased capacity among current producers
- Capacity added during ongoing maintenance
- Global cooperation
- Additional Federal funding in 2017 of additional/innovative sources
Encourage Planning for Both FDA Approval and CMS Coverage

• Meeting held on: Pathways for Successful Translation of New Imaging Agents and Modalities: Phase III Studies – held at NCI Headquarters in conjunction with the National Cancer Institute and the World Medical Isotope Society

• Reaching out to CMS to participate in Round Table Discussion on Targeted Radiotherapy: From Research to Clinical Practice on September 12, 2017
Seek Appropriate Reimbursement

• Expanding interactions with private and public payers on coverage and payment issues

• Continuing to seek appropriate coding for new procedures and radiopharmaceuticals through CMS and CPT processes

• Seeking appropriate valuations of procedures with the RUC

• Working with CORAR, MITA and others to seek legislation mandating more appropriate reimbursement for high cost radiopharmaceuticals
Enhance State Level Activity

• As technologists licensure efforts have moved from the Federal to the State level we have beefed-up staffing in that area.

• Working more closely with ASRT

• Developing model state licensure language

• Dealing with some efforts to:
  – Withdraw state licensure mandates in some states that are reducing their budgets
  – Expand the scope of practice of non-technologists to include performing imaging
<table>
<thead>
<tr>
<th>Increase Visibility with Federal Policy Makers</th>
<th>Address U.S. Pharmacopeia Compounding Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Joined ad-Hoc Coalition to Support Medical Research</td>
<td>• At SNMMI’s suggestion, USP has agreed to draft a new chapter on radiopharmaceutical compounding</td>
</tr>
<tr>
<td>• Submitted Congressional Testimony supporting NIH funding</td>
<td>• Members are being nominated to the drafting panel</td>
</tr>
<tr>
<td>• Considering joining other broader coalitions on issues such as malpractice and problems with Stark Law</td>
<td></td>
</tr>
</tbody>
</table>
The Affordable Care Act Appears to be Here to Stay

Figure 7
More of the Public Have Favorable Views than Unfavorable Views of ACA

As you may know a health reform bill was signed into law in 2010, known commonly as the Affordable Care Act or Obamacare. Given what you know about the health reform law, do you have a generally favorable or generally unfavorable opinion of it?

![Graph showing favorable, unfavorable, and don't know/refused views over time.]

It is Time to Start Working on Improving the Current System

Figure 9

Most Want Republicans and Democrats to Work Together to Improve ACA

Which of the following comes closer to your view?

- Republicans in Congress should work with Democrats to make improvements to the ACA, but not repeal it
- Republicans in Congress should continue working on their own plan to repeal and replace the ACA
- Republicans in Congress should move on from health care to work on other priorities

<table>
<thead>
<tr>
<th></th>
<th>Total</th>
<th>Work Together</th>
<th>Move On</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Democrats</strong></td>
<td>70%</td>
<td>26%</td>
<td>2%</td>
</tr>
<tr>
<td><strong>Independents</strong></td>
<td>59%</td>
<td>19%</td>
<td>20%</td>
</tr>
<tr>
<td><strong>Republicans</strong></td>
<td>34%</td>
<td>49%</td>
<td>15%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Work Together</th>
<th>Move On</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Trump supporters</strong></td>
<td>33%</td>
<td>46%</td>
</tr>
<tr>
<td><strong>Non-Trump supporters</strong></td>
<td>70%</td>
<td>7%</td>
</tr>
</tbody>
</table>

NOTE: Don’t know/Refused responses not shown.
SOURCE: Kaiser Family Foundation Health Tracking Poll (conducted August 1-6, 2017)
**Domain: Outreach**

**Goal E:** Patients and the medical community **recognize the value** of nuclear medicine, molecular imaging and radionuclide therapy

**Objectives:**

- Increase the number of patients advocating in support of the value of radiopharmaceuticals
- Increase referring physicians’ awareness of new radiopharmaceuticals
- Improve collaboration with other medical societies
- Increase SNMMI’s outreach efforts and resources within the imaging community
- Increase outreach to hospital administrators
- Expand financial resources dedicated to outreach activities
Patient Outreach

• **Patient Advocacy Advisory Board**
  – Eleven major patient advocacy organizations that advise us on patient-specific program development.

• **Programs:**
  – Patient Portal: Patient-focused website (DiscoverMI.org) to explain molecular imaging and therapies for each disease
  – Fact Sheets: Modality- and disease-specific brochures in print and online, 8 fact sheets now available in Spanish *NEW: Radiation Safety Factsheet and What is a Cardiac Stress Test*
  – Interactive Webinars: Allow patients to learn more and ask questions
  – Patient Education Day: Patient-focused track at our Annual Meeting; overview of nuclear medicine and breakout sessions (120 attendees)
Patient and Caregiver Survey

• 700+ Responses

• NET data accepted as Abstract at NANETs 2017 and will be published in *Pancreas*

• Results showed that:
  – 39% imaging patients reported getting no info, only 3.5% of therapy patients got no info
  – Of the patients that only received imaging, over 50% had concerns about the

Conclusion: Patient concerns about nuclear medicine safety are not being adequately addressed. Considerations should be made by prescribing physician to address patient concerns.
Expert working groups with referring physician members

- Targeted Radioisotope Therapy Outreach
- Brain Imaging Outreach
- Prostate Cancer Outreach
- Bone Scan Outreach
- HIDA Outreach
- V/Q Outreach
- PET/CT for Restaging of Malignant Disease Outreach

- Additional working groups will be created as needed
Referral Barriers Survey

Which of the following issues do you find to be barriers to referrals to nuclear medicine and molecular imaging?

- Other
- Patient Concerns Regarding Radiation Exposure
- High Number of False Positives
- Questions Regarding the Ability to Accurately Read the Test Results
- Questions Regarding Quality of the Tests
- Scheduling Issues (Long Waits)
- Lack of Geographical Access
- Lack of Physician Understanding of the Uses/Indications of NM and MI
- Procedures Not Part of Standard Protocol at Hospitals/Practices
- Image/Procedures Not Covered by Insurance

Focusing outreach tactics to address top 3 barriers to referrals identified in survey:
- Lack of physician understanding of NM
- Procedures not part of standard protocol
- Not covered by insurance
Domain: Organizational Strength and Stability

Goal F: SNMMI has the organizational strength and sustainability to lead the field in a dynamic healthcare landscape

Objectives:
- Strengthen membership numbers
- Ensure financial stability
- Ensure an effective organizational structure
• **Journal of Nuclear Medicine Technology**
  - Focus entirely on nuclear medicine technology
  - More than 40 peer-reviewed articles per year

• **Molecular Imaging**
  - An official journal of the SNMMI, now published by SAGE
  - Basic and translational studies – novel results and concepts

• **SNMMI books**
  - Required reading for most technologist education programs
  - New e-book series, free to members: Quality, Safety, and Dose Optimization
Nearly $400,000 is disbursed annually to grants, awards, and scholarship recipients.

Major research grants, disbursed over multiple years, include:

- Molecular Imaging Research Grant for Junior Academic Faculty $105,000
- Postdoctoral Molecular Imaging Scholar Program $65,000
- Predoctoral Molecular Imaging Scholar Program $45,000
- Mitzi & William Blahd Pilot Research Grant $25,000

Please visit [www.snmmi.org/grants](http://www.snmmi.org/grants) for the full list and opening/closing dates.
In 2017 the Education and Research Foundation of Nuclear Medicine and Molecular Imaging Foundation (ERF) provided funding of $269,866 to SNMMI. This funding is directed to endowed and non-endowed awards disbursed to over 210 individuals and institutions. ERF has pledged continued support for 2018, totaling $279,724.
SNMMI History Archives Project

SNMMI’S History Archives Project

SNMMI, the Education and Research Foundation (ERF), and nuclear medicine in general, have a rich and exciting history involving a number of Nobel Prize winners. We have a responsibility to maintain and celebrate this history by making these vitally important archives – which include work by the pioneers of molecular science, including Saul Hertz, Henry Wagner, Hal Anger, Dennis Patton and Michel ter-Pogossian – permanently accessible. The History Archives Project will achieve this critical work.

SNMMI Historian Frederic Fahey is leading this multi-year, multi-phase project, which includes the organization and digitization of historical materials in our archives, including original hardcopy photos and documents, the development of an archival search tool to aid in the location and interpretation of data, the development of web-based and physical exhibits, and the appropriate and safe storage of archival materials.

Please visit www.SNMMI.org/history to learn more about SNMMI’s history.
The Heritage Fund

To support and maintain the History Archives Project, SNMMI and ERF are building the Nuclear Medicine and Molecular Imaging Heritage Fund. In the short-term we will be raising funds to support the next phase of the organization and processing work of the History Archives Project.

Longer term this will be followed by an effort to raise funding that ensures long-term and continuing accession, management, use and preservation of the SNMMI archives. Individual SNMMI members, corporate partners and foundations will be afforded opportunities to support the Heritage Fund.

To make a contribution to the Heritage Fund, please visit [www.snmmi.org/donate](http://www.snmmi.org/donate), or contact SNMMI Development at 703-326-1194, or ldilworth@snmmi.org.
SNMMI provides comprehensive news for SNMMI members and the wider nuclear medicine/molecular imaging community.

- **SNMMI SmartBriefs**
  - Daily news for 16,000+ subscribers
- **SNMMI’s social networks**
  - LinkedIn community – 11,250+ members
  - Facebook community – 13,500+ likes
  - Twitter – 2,750+ followers
  - New Instagram site – 600+
  - YouTube site: SNMChannel1
- **SNMMI Newsline (JNM)**
  - Reaches 20,000+ each month
SNMMI is committed to providing informative and helpful information to its members. We surveyed, tracked, and analyzed. Our goals:

- **Website content:**
  - Refine and streamline

- **Newsletters:**
  - Redefine in member-preferred format

- **Email blasts:**
  - Target to ensure members get the news that’s most interesting to them

- **New member communication platform**
  - To be implemented in 2018
2018 Mid-Winter Meeting

Theme: Theranostics
Date: January 25-27, 2018 (2.5 days)
Registration Opens: September 15

www.snmmi.org/mwm
2018 Annual Meeting

Dates: June 23-26, 2018
Location: Philadelphia, PA
Registration Opens: November 1

www.snmmi.org/am

• 20% of the sessions planned by each group be “Nuts and Bolts” sessions.

• CE Education will begin earlier (Saturday afternoon).

• Highlights Lecture will be held Tuesday evening.
SNMMI offers several networking opportunities during its annual meeting targeted towards all member types:

- Exhibit/Poster Hall Welcome Reception
- “Hot Trot 5K” Run/Walk
- RPSC/CMIIT Poster Mixer
- Exhibitor User Meetings
- SNMMI First Timer’s/New Member’s Orientation
- ACNM/NMRO Networking Lunch
- Meet the Author/Poster Awards

…..and more!
### SNMMI Annual Meeting Dates/Locations

<table>
<thead>
<tr>
<th>Year</th>
<th>Destination</th>
<th>Meeting Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>Philadelphia, PA</td>
<td>June 23 –26</td>
</tr>
<tr>
<td>2019</td>
<td>Anaheim, CA</td>
<td>June 22 –25</td>
</tr>
<tr>
<td>2020</td>
<td>New Orleans, LA</td>
<td>TBD</td>
</tr>
<tr>
<td>2021</td>
<td>Washington, DC</td>
<td>June 12-15</td>
</tr>
<tr>
<td>2022</td>
<td>Vancouver, BC Canada</td>
<td>June 11-14</td>
</tr>
<tr>
<td>2023</td>
<td>Chicago, IL</td>
<td>TBD</td>
</tr>
</tbody>
</table>

### SNMMI Mid-Winter Meeting Dates/Locations

<table>
<thead>
<tr>
<th>Year</th>
<th>Destination</th>
<th>Hotel</th>
<th>Meeting Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>Orlando, FL</td>
<td>Hilton Walt Disney World</td>
<td>January 25-27</td>
</tr>
<tr>
<td>2019</td>
<td>Palm Springs, CA</td>
<td>Renaissance Palm Springs</td>
<td>January 17-19</td>
</tr>
<tr>
<td>2020</td>
<td>Tampa, FL</td>
<td>Marriott Tampa Waterside</td>
<td>January 23-25</td>
</tr>
</tbody>
</table>
Get Involved – SNMMI Needs YOU!

The SNMMI is ALWAYS looking for volunteers.

If you are interested in volunteering for an SNMMI Committee, please contact Nikki Wenzel-Lamb, Director of Leadership at nwenzel-lamb@snmmi.org.

A formal call for volunteers will be distributed in February 2018.
FROM THE BOARD

THANK YOU

TO CHAPTER LEADERS